Description: This publication reports a study using a computer simulation model to investigate whether the cardiovascular benefits observed with empagliflozin in the EMPA-REG OUTCOME trial can be explained by its effects on multiple cardiometabolic risk factors. The study uses the Michigan Model for Diabetes to simulate trial outcomes and assess the contribution of changes in risk factors such as weight, HbA1c, blood pressure, and cholesterol to the observed cardiovascular effects.

Citation: Kuo, S., Ye, W., Duong, J., & Herman, W. H. (2018). Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes research and clinical practice, 141, 181–189. https://doi.org/10.1016/j.diabres.2018.04.040